Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

Abstract Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. Th...

Full description

Bibliographic Details
Main Authors: Shannon L. Reynolds, Sameer R. Ghate, Richard Sheer, Pranav K. Gandhi, Chad Moretz, Cheng Wang, Stephen Sander, Mary E. Costantino, Srinivas Annavarapu, George Andrews
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Health and Quality of Life Outcomes
Subjects:
Dabigatran
Warfarin
Healthcare resource utilization
Non-valvular atrial fibrillation
Online Access:http://link.springer.com/article/10.1186/s12955-017-0705-x

Internet

http://link.springer.com/article/10.1186/s12955-017-0705-x

Similar Items